Diasorin

Name: Diasorin
Address: Strada Crescentino snc, Saluggia, 13040, IT
Telephone: +390161487093
Price range: Not Applicable

Casa
Italia
Saluggia
Diasorin

Global leader in the laboratory diagnostics market. Starting from 2021, the company also commercializes Life Science products.

DiaSorin is an Italian multinational biotechnology company that produces and markets in vitro diagnostics reagent kits used in immunodiagnostics and molecular diagnostics. The Group was founded in 1968 and is headquartered in Saluggia (Italy). Its line of products used by diagnostic laboratories that are part of hospital facilities or operate independently can meet the needs of the following clini

cal areas: infectious diseases, cardiac markers, bone metabolism, hepatitis and retrovirus, oncology and endocrinology. DiaSorin can offer the market an assay menu that is unique for its width and presence of specialty tests, which identify us as “the” in vitro diagnostics specialist. DiaSorin also provides Life Science products that have a wide range of applications including academic and scientific research, public health and food safety, plant pathogens detection and cell counts, viability, and cell health analyses.

03/09/2026

Exploring flexible approaches to gastrointestinal testing
As healthcare systems increasingly focus on value-based care, diagnostic strategies are being reassessed to better align with patient needs and resource considerations.

In this video, Dr. David Pride shares how gastrointestinal (GI) testing is evolving toward patient-centered approaches. Moving beyond one-size-fits-all models may support more intentional testing and balanced resource utilization.

Listen to the discussion: https://hubs.li/Q04t6LgV0

01/09/2026

Did you know that sepsis claims more lives annually than breast cancer, prostate cancer, and HIV combined?

This Sepsis Awareness Month, we’re spotlighting the power of education, collaboration, and innovation across the healthcare ecosystem to improve patient outcomes.

At Diasorin, we’re committed to supporting lab professionals and clinicians with advanced tools that empower faster, more confident decision-making when it matters most.

Do you know the signs and symptoms of sepsis? Learn more at Sepsis Alliance: https://hubs.li/Q04w4L9b0

29/08/2026

The ongoing Cyclospora outbreak highlights an important challenge in gastrointestinal diagnostics: accurately detecting parasitic infections when traditional testing methods may be difficult to scale and can potentially miss positive cases.

Molecular testing offers an alternative approach, helping laboratories enhance detection capabilities while managing increased testing demands.

In our latest blog, Dr. Michelle Tabb shares insights into what this outbreak can teach us about GI testing today and why diagnostic flexibility is becoming increasingly important for clinical laboratories.

Read more: https://hubs.li/Q04vNsMt0

25/08/2026

Congenital cytomegalovirus (cCMV) is the leading infectious cause of childhood hearing loss worldwide.

Join Dr. Kenneth Gavina for an upcoming webinar exploring the clinical impact of cCMV, current newborn screening approaches for earlier detection and intervention, and a pooled saliva PCR methodology designed to help expand cCMV screening capacity.

Reserve your spot today: https://hubs.li/Q04vckPv0

19/08/2026

Diagnostic stewardship is widely recognized as essential to clinical care, but implementation can be complex in practice.

In this episode, filmed live at ASM Microbe 2026, Dr. David C. Gaston, Dr. Allison B. Chambliss, and Dr. Linoj P. Samuel examine how healthcare organizations are moving beyond one-size-fits-all testing approaches to adopt more flexible strategies that better align with patient needs and clinical decision-making.

Listen as they discuss:
• Key challenges in operationalizing diagnostic stewardship
• The role of flexible syndromic testing in supporting tailored diagnostic approaches
• Considerations for integrating adaptable testing into clinical workflows

Listen wherever you get your podcasts: https://hubs.li/Q04tBZRC0

18/08/2026

The Cyclospora outbreak highlights the continued need for diagnostic strategies that require comprehensive parasite detection.

In settings where clinicians must make timely decisions with limited information, diagnostic testing can help identify parasites that might otherwise go undetected.

The LIAISON PLEX® Gastrointestinal Flex Assay is designed to enable flexible GI pathogen testing where Cyclospora is front and center to our industry leading approach to parasite detection.

Learn more: https://hubs.li/Q04tjFF90

14/08/2026

Gastrointestinal (GI) diagnostics continue to evolve as clinicians and laboratories work to balance clinical relevance with operational efficiency.

Dr. David Pride, Director of Microbiology at UC San Diego Health, discusses the shift away from broad, one-size-fits-all panels and the value of more flexible GI testing strategies. His perspective highlights how targeted approaches may support clinical decision-making while helping laboratories manage workflow and resources.

Learn more: https://hubs.li/Q04t6BlJ0

13/08/2026

What Trends Should Labs Watch for in GI Diagnostics?

GI diagnostics continues to evolve. From growing demand for flexibility to intentional testing approaches, discover the trends shaping the future of GI testing.

🎥 Watch episode 6 of "Why the Cyclospora Outbreak Pushes Us to Rethink GI Diagnostics" now to learn more!

11/08/2026

Why Customizable GI Testing Matters?

Not every patient, pathogen, or clinical scenario is the same. Discover how customizable GI testing can help laboratories move beyond a one-size-fits-all approach to deliver more targeted, meaningful results.

🎥 Watch episode 5 of "Why the Cyclospora Outbreak Pushes Us to Rethink GI Diagnostics" now to learn more! https://hubs.li/Q04sGzLD0

10/08/2026

New peer-reviewed findings in Microbiology Spectrum highlight how the Simplexa® C. auris Direct assay is helping laboratories address one of today’s most urgent infection-prevention challenges.

As a De Novo IVD assay for Candida auris colonization detection, Simplexa® C. auris Direct provides a standardized solution for detecting patients suspected of C. auris colonization, helping healthcare facilities act quickly to prevent transmission and protect vulnerable patients.

Key results:
• 100% sensitivity vs. culture followed by MALDI-TOF identification
• 95% overall diagnostic accuracy
• Strong agreement with culture and PCR LDTs
• No cross-reactivity with other fungi or bacteria
• No environmental contamination detected during testing

The assay showed strong agreement with LDTs and a streamlined workflow on the LIAISON® MDX platform—enabling faster screening to support confident infection‑control decisions and safer patient care.

Explore the full publication: https://hubs.li/Q04svPnd0

Indirizzo

Strada Crescentino Snc
Saluggia
13040

Telefono

+390161487093

Sito Web

http://www.diasorin.com/

Notifiche

Lasciando la tua email puoi essere il primo a sapere quando Diasorin pubblica notizie e promozioni. Il tuo indirizzo email non verrà utilizzato per nessun altro scopo e potrai annullare l'iscrizione in qualsiasi momento.